Aptose Biosciences Reports 100% Response Rate for Tuspetinib Triple Therapy in Newly Diagnosed AML
I'm PortAI, I can summarize articles.
Aptose Biosciences Inc. reported a 100% response rate for its tuspetinib triple therapy in newly diagnosed AML patients ineligible for induction chemotherapy. The therapy, combining tuspetinib with venetoclax and azacitidine, showed efficacy across various AML populations, including those with adverse genetic mutations. Safety was notable, with febrile neutropenia in 16.7% of subjects. Preliminary findings at a higher dose showed early blast clearance and MRD-negativity. Results were presented at the 67th ASH Annual Meeting in December 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments